Adults with chronic acid sphingomyelinase deficiency show significant visceral, pulmonary, and hematologic improvements after enzyme replacement therapy with olipudase-alfa: 1-year results of the ASCEND placebo-controlled trial
| dc.authorid | 0000-0002-4660-821X | |
| dc.contributor.author | Wasserstein, Melissa | |
| dc.contributor.author | Arash-Kaps, Laila | |
| dc.contributor.author | Barbato, Antonio | |
| dc.contributor.author | Gallagher, Renata C. | |
| dc.contributor.author | Giugliani, Roberto | |
| dc.contributor.author | Guelbert, Norberto B. | |
| dc.contributor.author | Hollak, Carla | |
| dc.date.accessioned | 2025-05-10T19:43:56Z | |
| dc.date.issued | 2021 | |
| dc.department | İstanbul Medeniyet Üniversitesi | |
| dc.description | 17th Annual Research Meeting of the We're-Organizing-Research-for-Lysosomal-Diseases-Symposium (WORLDSymposium) -- FEB 07-12, 2021 -- ELECTR NETWORK | |
| dc.description.abstract | [No abstract available] | |
| dc.description.sponsorship | Were Organizing Res Lysosomal Dis Symposium+ | |
| dc.identifier.doi | 10.1016/j.ymgme.2020.12.271 | |
| dc.identifier.endpage | S110 | |
| dc.identifier.issn | 1096-7192 | |
| dc.identifier.issn | 1096-7206 | |
| dc.identifier.issue | 2 | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.startpage | S110 | |
| dc.identifier.uri | https://doi.org/10.1016/j.ymgme.2020.12.271 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14730/10779 | |
| dc.identifier.volume | 132 | |
| dc.identifier.wos | WOS:000614651500267 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.language.iso | en | |
| dc.publisher | Academic Press Inc Elsevier Science | |
| dc.relation.ispartof | Molecular Genetics and Metabolism | |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.snmz | KA_WOS_20250302 | |
| dc.title | Adults with chronic acid sphingomyelinase deficiency show significant visceral, pulmonary, and hematologic improvements after enzyme replacement therapy with olipudase-alfa: 1-year results of the ASCEND placebo-controlled trial | |
| dc.type | Conference Object |










